Mitosin, a novel marker of cell proliferation and early recurrence in intracranial meningiomas

Konstantinidou, AE; Korkolopoulou, P; Kavantzas, N; Mahera, H; Thymara, I; Kotsiakis, X; Perdiki, M; Patsouris, E; Davaris, P

dc.contributor.author	Konstantinidou, AE	en
dc.contributor.author	Korkolopoulou, P	en
dc.contributor.author	Kavantzas, N	en
dc.contributor.author	Mahera, H	en
dc.contributor.author	Thymara, I	en
dc.contributor.author	Kotsiakis, X	en
dc.contributor.author	Perdiki, M	en
dc.contributor.author	Patsouris, E	en
dc.contributor.author	Davaris, P	en
dc.date.accessioned	2014-03-01T01:53:09Z
dc.date.available	2014-03-01T01:53:09Z
dc.date.issued	2003	en
dc.identifier.issn	0213-3911	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/26869
dc.subject	mitosin	en
dc.subject	meningiomas	en
dc.subject	proliferation	en
dc.subject	recurrence	en
dc.subject	survival	en
dc.subject.classification	Cell Biology	en
dc.subject.classification	Pathology	en
dc.subject.other	TOPOISOMERASE-II-ALPHA	en
dc.subject.other	NUCLEAR ANTIGEN	en
dc.subject.other	BRAIN-TUMORS	en
dc.subject.other	PROGNOSTIC-SIGNIFICANCE	en
dc.subject.other	KI-67	en
dc.subject.other	IMMUNOREACTIVITY	en
dc.subject.other	PROGRESSION	en
dc.subject.other	EXPRESSION	en
dc.subject.other	KINETICS	en
dc.subject.other	SURVIVAL	en
dc.title	Mitosin, a novel marker of cell proliferation and early recurrence in intracranial meningiomas	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2003	en
heal.abstract	The expression of mitosin, a novelproliferation-associated molecule was evaluated immunohistochemically in a consecutive series of 47 patients with primary intracranial benign and atypical meningiomas. Mitosin expression was correlated with proliferation markers Ki-67 (MIB-1), proliferating cell nuclear antigen (PCNA), topoisomerase IIalpha (TopoIIalpha) and mitotic index, as well as with standard clinicopathological parameters and patient outcome. Seven tumors recurred (14.8%) following gross total resection, within a follow-up period ranging from 21 to 108 months (median 60 months). The higher proliferation indices were obtained with mitosin and PCNA and the lower ones with Topolla. Mitosin labeling index (LI) ranged from 0.1 to 57% (median 3%), with a significant overlapping of values between grades. A significant positive correlation was shown between mitosin LI on the one hand and Ki-67 LI (p<0.001), or the mitotic index (p=0.027) on the other. The incidence of recurrence was higher in cases with a mitosin Li higher than 3% (p=0.048). Univariate analysis disclosed mitosin LI (p=0.033) along with the mitotic index (p=0.024) and tumor size (p=0.028) as significant predictors of shortened recurrence-free survival. In multivariate analysis, the labeling indices of mitosin (p=0.035) and Ki-67 (p=0.032), along with tumor size, were shown to provide independent prognostic information, beyond that obtained by standard clinical and pathological parameters. However, as indicated by factor analysis, the prognostic information yielded by mitosin was superior to that provided by the remaining proliferation markers (p=0.041). We conclude that mitosin immunohistochemical expression, although failing to discriminate between benign and atypical meningiomas, may be of use as a novel cell proliferation marker and as a predictor of tumor recurrence.	en
heal.publisher	F HERNANDEZ	en
heal.journalName	HISTOLOGY AND HISTOPATHOLOGY	en
dc.identifier.isi	ISI:000180340500008	en
dc.identifier.volume	18	en
dc.identifier.issue	1	en
dc.identifier.spage	67	en
dc.identifier.epage	74	en